What is HC Wainwright’s Forecast for SCPH Q1 Earnings?

scPharmaceuticals Inc. (NASDAQ:SCPH) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for scPharmaceuticals in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for scPharmaceuticals’ current full-year earnings is ($1.53) per share. HC Wainwright also issued estimates for scPharmaceuticals’ Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.11) EPS and Q4 2026 earnings at ($0.05) EPS.

Separately, Maxim Group lowered their price objective on shares of scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, March 20th.

scPharmaceuticals Price Performance

Shares of SCPH opened at $3.22 on Friday. The company has a market capitalization of $169.99 million, a price-to-earnings ratio of -1.69 and a beta of 0.17. scPharmaceuticals has a fifty-two week low of $1.94 and a fifty-two week high of $5.65. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The business’s 50-day moving average is $2.60 and its 200-day moving average is $3.16.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.06). scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The business had revenue of $11.75 million during the quarter, compared to analysts’ expectations of $11.63 million.

Institutional Trading of scPharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Chicago Partners Investment Group LLC purchased a new position in scPharmaceuticals in the first quarter valued at about $31,000. Assenagon Asset Management S.A. acquired a new position in scPharmaceuticals in the 1st quarter worth about $33,000. Legato Capital Management LLC purchased a new stake in shares of scPharmaceuticals during the 4th quarter worth about $37,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of scPharmaceuticals during the 4th quarter valued at about $38,000. Finally, Perkins Capital Management Inc. lifted its holdings in shares of scPharmaceuticals by 41.0% during the 1st quarter. Perkins Capital Management Inc. now owns 17,200 shares of the company’s stock valued at $45,000 after buying an additional 5,000 shares during the last quarter. 89.52% of the stock is currently owned by hedge funds and other institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.